Studies have shown the presence of the inactivate protein product of CDKN2A gene, namely p16INK4a, in 95% of sporadic pancreatic cancers; however, germline CDKN2A mutations in these cases are rare (Bartsch et al. 2002). This evidence concerns the gene CDKN2A and pancreatic neoplasm.